Modern Pathogenetic Concepts of Liver Fibrosis Suggest Stellate Cells and TGF-beta As Major Players and Therapeutic Targets

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2006 Mar 28

PMID 16563223

Citations 296

Authors

A M Gressner

R Weiskirchen

Affiliations

Soon will be listed here.

Abstract

Hepatic fibrosis is a scarring process that is associated with an increased and altered deposition of extracellular matrix in liver. At the cellular and molecular level, this progressive process is mainly characterized by cellular activation of hepatic stellate cells and aberrant activity of transforming growth factor-beta1 and its downstream cellular mediators. Although the cellular responses to this cytokine are complex, the signalling pathways of this pivotal cytokine during the fibrogenic response and its connection to other signal cascades are now understood in some detail. Based on the current advances in understanding the pleiotropic reactions during fibrogenesis, various inhibitors of transforming growth factor-beta were developed and are now being investigated as potential drug candidates in experimental models of hepatic injury. Although it is too early to favour one of these antagonists for the treatment of hepatic fibrogenesis in human, the experimental results obtained yet provide stimulatory impulses for the development of an effective treatment of choice in the not too distant future. The present review summarises the actual knowledge on the pathogenesis of hepatic fibrogenesis, the role of transforming growth factor-beta and its signalling pathways in promoting the fibrogenic response, and the therapeutic modalities that are presently in the spotlight of many investigations and are already on the way to take the plunge into clinical studies.

Citing Articles

Cytokine modulation in pelvic organ prolapse and urinary incontinence: from molecular insights to therapeutic targets.

Chen Y, Ullah A, Chen W, Xuan J, Huang X, Liang S Mol Med. 2024; 30(1):214.

PMID: 39538179 PMC: 11562709. DOI: 10.1186/s10020-024-00989-3.

A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Doueiry C, Kappler C, Martinez-Morant C, Duncan S Int J Mol Sci. 2024; 25(13).

PMID: 39000384 PMC: 11242544. DOI: 10.3390/ijms25137277.

Effect of hepatocyte damage in hepatic fibrogenesis of patients infected with .

Lu Y, Tang W, Zhang H, Liu J, Zhong S Infect Immun. 2024; 92(6):e0002624.

PMID: 38767360 PMC: 11237810. DOI: 10.1128/iai.00026-24.

Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.

Ferreira J, Bicho M, Serejo F Viruses. 2024; 16(3).

PMID: 38543737 PMC: 10974411. DOI: 10.3390/v16030371.

Fibrous Remodeling in Eosinophilic Esophagitis: Clinical Facts and Pathophysiological Uncertainties.

Arias-Gonzalez L, Rodriguez-Alcolado L, Laserna-Mendieta E, Navarro P, Lucendo A, Grueso-Navarro E Int J Mol Sci. 2024; 25(2).

PMID: 38256003 PMC: 10815180. DOI: 10.3390/ijms25020927.

References

Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K . Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology. 2001; 120(7):1784-800. DOI: 10.1053/gast.2001.24832. View

Dubuisson L, Boussarie L, Bedin C, Balabaud C, Bioulac-Sage P . Transformation of sinusoids into capillaries in a rat model of selenium-induced nodular regenerative hyperplasia: an immunolight and immunoelectron microscopic study. Hepatology. 1995; 21(3):805-14. View

Pinzani M, Rombouts K . Liver fibrosis: from the bench to clinical targets. Dig Liver Dis. 2004; 36(4):231-42. DOI: 10.1016/j.dld.2004.01.003. View

de Caestecker M, Piek E, Roberts A . Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst. 2000; 92(17):1388-402. DOI: 10.1093/jnci/92.17.1388. View

Borkham-Kamphorst E, Stoll D, Gressner A, Weiskirchen R . Inhibitory effect of soluble PDGF-beta receptor in culture-activated hepatic stellate cells. Biochem Biophys Res Commun. 2004; 317(2):451-62. DOI: 10.1016/j.bbrc.2004.03.064. View

Hendriks H, Verhoofstad W, Brouwer A, de Leeuw A, Knook D . Perisinusoidal fat-storing cells are the main vitamin A storage sites in rat liver. Exp Cell Res. 1985; 160(1):138-49. DOI: 10.1016/0014-4827(85)90243-5. View

Reeves H, Friedman S . Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci. 2002; 7:d808-26. DOI: 10.2741/reeves. View

Janoschek N, Van de Leur E, Gressner A, Weiskirchen R . Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system. Biochem Biophys Res Commun. 2004; 316(4):1107-15. DOI: 10.1016/j.bbrc.2004.02.147. View

Ueberham E, Low R, Ueberham U, Schonig K, Bujard H, Gebhardt R . Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology. 2003; 37(5):1067-78. DOI: 10.1053/jhep.2003.50196. View

10.

Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner A, Dooley S . Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional.... J Biol Chem. 2000; 275(38):29308-17. DOI: 10.1074/jbc.M003282200. View

11.

Friedman S . Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2005; 1(2):98-105. DOI: 10.1038/ncpgasthep0055. View

12.

Zavadil J, Bottinger E . TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24(37):5764-74. DOI: 10.1038/sj.onc.1208927. View

13.

Akhurst R, Derynck R . TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001; 11(11):S44-51. DOI: 10.1016/s0962-8924(01)02130-4. View

14.

Desmet V, Roskams T . Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004; 40(5):860-7. DOI: 10.1016/j.jhep.2004.03.007. View

15.

Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View

16.

Uemura M, Swenson E, Gaca M, Giordano F, Reiss M, Wells R . Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell. 2005; 16(9):4214-24. PMC: 1196331. DOI: 10.1091/mbc.e05-02-0149. View

17.

Iredale J, Benyon R, Pickering J, McCullen M, Northrop M, Pawley S . Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998; 102(3):538-49. PMC: 508915. DOI: 10.1172/JCI1018. View

18.

Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner A, Weiskirchen R . Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest. 2004; 84(6):766-77. DOI: 10.1038/labinvest.3700094. View

19.

Ward C, Robertson H, Forrest I, Lordan J, Murphy D, Dark J . Hypothesis: epithelial-to-mesenchymal transition is a common cause of chronic allograft failure. Transplant Proc. 2005; 37(2):977-80. DOI: 10.1016/j.transproceed.2004.12.203. View

20.

Dooley S, Delvoux B, Lahme B, Gressner A . Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology. 2000; 31(5):1094-106. DOI: 10.1053/he.2000.6126. View